Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Seezary syndrome

被引:44
作者
Child, F. [1 ]
Ortiz-Romero, P. L. [2 ]
Alvarez, R. [3 ]
Bagot, M. [4 ]
Stadler, R. [5 ]
Weichenthal, M. [6 ]
Alves, R. [7 ]
Quaglino, P. [8 ]
Beylot-Barry, M. [9 ]
Cowan, R. [10 ]
Geskin, L. J. [11 ]
Perez-Ferriols, A. [12 ]
Hellemans, P. [13 ]
Elsayed, Y. [14 ]
Phelps, C. [14 ]
Forslund, A. [15 ]
Kamida, M. [16 ]
Zinzani, P. L. [17 ]
机构
[1] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England
[2] Univ Complutense, Inst I 12, Hosp 12 Octubre, Dept Dermatol,Med Sch, Madrid, Spain
[3] Portuguese Inst Oncol, Lisbon, Portugal
[4] Univ Paris 07, St Louis Hosp, Dept Dermatol, Paris, France
[5] Johannes Wesling Med Ctr, Dept Dermatol, Minden, Germany
[6] Univ Hosp Schleswig Holstein, Dept Dermatol, Kiel, Germany
[7] Ctr Hosp Porto, Hosp Santo Antonio, Dept Dermatol, Oporto, Portugal
[8] Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy
[9] Univ Hosp Bordeaux, Dept Dermatol, Bordeaux, France
[10] Christie Hosp, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[11] Univ Pittsburgh, Sch Med, Dept Dermatol, Pittsburgh, PA 15261 USA
[12] Univ Gen Hosp, Dept Dermatol, Valencia, Spain
[13] Janssen Res & Dev, Beerse, Belgium
[14] Janssen Res & Dev, Titusville, NJ USA
[15] Janssen Res & Dev, Spring House, PA USA
[16] Janssen Pharmaceut KK, Tokyo, Japan
[17] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy
关键词
T-CELL LYMPHOMA; SUBEROYLANILIDE HYDROXAMIC ACID; ADVANCED SOLID TUMORS; CUTANEOUS-LYMPHOMAS; INTERNATIONAL-SOCIETY; EUROPEAN-ORGANIZATION; MULTIPLE-MYELOMA; SEZARY-SYNDROME; TASK-FORCE; JNJ-26481585;
D O I
10.1111/bjd.14427
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor. Objectives To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). Methods Patients received quisinostat 8 mg or 12 mg on days 1, 3 and 5 of each week in 21-day treatment cycles. Primary efficacy end point was cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT). Secondary end points included global RR, duration of response (DOR) in skin, progression-free survival (PFS), pruritus relief, safety and pharmacodynamic markers. Results Eight of 26 (25 evaluable) patients achieved >= 50% reduction in mSWAT score at least once, with confirmed cutaneous response in six (RR 24%). There was a low global RR of 8%. DOR in skin ranged from 2.8 to 6.9 months. Median PFS was 5.1 months. Pruritus relief was more frequent in cutaneous responders (67%) than nonresponders (32%). Serial tumour biopsies revealed an increase in acetylated tubulin, indicating a target effect of histone deacetylase 6. Twenty-one of 26 (81%) patients were withdrawn from the study before or at clinical cut-off; five (19%) continued to receive treatment with quisinostat. The most common drug-related adverse events were nausea, diarrhoea, asthenia, hypertension, thrombocytopenia and vomiting. Grade 3 drug-related adverse events included hypertension, lethargy, pruritus, chills, hyperkalaemia and pyrexia. Conclusions Quisinostat 12 mg three times weekly is active in the treatment of patients with relapsed or refractory CTCL, with an acceptable safety profile. Combination therapy with other drugs active in CTCL may be appropriate.
引用
收藏
页码:80 / 88
页数:9
相关论文
共 30 条
[1]   JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity [J].
Arts, Janine ;
King, Peter ;
Marien, Ann ;
Floren, Wim ;
Belien, Ann ;
Janssen, Lut ;
Pilatte, Isabelle ;
Roux, Bruno ;
Decrane, Laurence ;
Gilissen, Ron ;
Hickson, Ian ;
Vreys, Veronique ;
Cox, Eugene ;
Bol, Kees ;
Talloen, Willem ;
Goris, Ilse ;
Andries, Luc ;
Du Jardin, Marc ;
Janicot, Michel ;
Page, Martin ;
van Emelen, Kristof ;
Angibaud, Patrick .
CLINICAL CANCER RESEARCH, 2009, 15 (22) :6841-6851
[2]   Comparative tissue distribution of the HDAC inhibitor JNJ-26481585 [J].
Bohets, H. ;
Van Uytsel, K. ;
De Meulder, M. ;
King, P. ;
Hickson, I. ;
Forslund, A. ;
Palmer, P. ;
McClue, S. .
EJC SUPPLEMENTS, 2010, 8 (07) :189-189
[3]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[4]   The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models [J].
Deleu, S. ;
Lemaire, M. ;
Arts, J. ;
Menu, E. ;
Van Valckenborgh, E. ;
King, P. ;
Vande Broek, I. ;
De Raeve, H. ;
Van Camp, B. ;
Croucher, P. ;
Vanderkerken, K. .
LEUKEMIA, 2009, 23 (10) :1894-1903
[5]   Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma [J].
Deleu, Sarah ;
Lemaire, Miguel ;
Arts, Janine ;
Menu, Eline ;
Van Valckenborgh, Els ;
Broek, IsabeHe Vande ;
De Raeve, Hendrik ;
Coulton, Les ;
Van Camp, Ben ;
Croucher, Peter ;
Vanderkerken, Karin .
CANCER RESEARCH, 2009, 69 (13) :5307-5311
[6]   Significant impact of cutaneous T-cell lymphoma on patients' quality of life - Results of a 2005 National Cutaneous Lymphoma Foundation Survey [J].
Demierre, Marie-France ;
Gan, Stephanie ;
Jones, Judy ;
Miller, Donald R. .
CANCER, 2006, 107 (10) :2504-2511
[7]   Prospects: Histone deacetylase inhibitors [J].
Dokmanovic, M ;
Marks, PA .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 96 (02) :293-304
[8]   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results [J].
Duvic, M ;
Hymes, K ;
Heald, P ;
Breneman, D ;
Martin, AG ;
Myskowski, P ;
Crowley, C ;
Yocum, RC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2456-2471
[9]   Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL) [J].
Duvic, Madeleine ;
Talpur, Rakshandra ;
Ni, Xiao ;
Zhang, Chunlei ;
Hazarika, Parul ;
Kelly, Cecilia ;
Chiao, Judy H. ;
Reilly, John F. ;
Ricker, Justin L. ;
Richon, Victoria M. ;
Frankel, Stanley R. .
BLOOD, 2007, 109 (01) :31-39
[10]   Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial [J].
Duvic, Madeleine ;
Dummer, Reinhard ;
Becker, Juergen C. ;
Poulalhon, Nicolas ;
Romero, Pablo Ortiz ;
Bernengo, Maria Grazia ;
Lebbe, Celeste ;
Assaf, Chalid ;
Squier, Margaret ;
Williams, Denise ;
Marshood, Miriam ;
Tai, Feng ;
Prince, H. Miles .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) :386-394